DOCSLIB.ORG

Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 24

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Statistical Analysis Plan: 20140254 Date: 07 January 2017 Page 24 Product: AMG 334 Clinical Study Report: 20140254 Primary Analysis Date: 13 April 2017 Page 1 16.1.9 Documentation of Statistical Methods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x ([HUFLVHLQGXFHGDQJLQD x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x &KDQJHIURPEDVHOLQHLQ7(7 6HFRQGDU\(QGSRLQWV x 'XULQJWKH(77 R 7LPHWRRQVHWRIH[HUFLVHLQGXFHGDQJLQD R 7LPHWRRQVHWRIPP67VHJPHQWGHSUHVVLRQ 6DIHW\(QGSRLQWV x $GYHUVHHYHQWVDQGGLVHDVHUHODWHGHYHQWV x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x 1XOO+\SRWKHVLV,QVXEMHFWVZLWKDQJLQD$0*GRHVVLJQLILFDQWO\GHFUHDVH H[HUFLVHFDSDFLW\ E\DWOHDVWVHFRQGV DVPHDVXUHGE\FKDQJHIURP EDVHOLQHLQWRWDOH[HUFLVHWLPHFRPSDUHGWRSODFHERDQGWKDWWKHWUXHWUHDWPHQW GLIIHUHQFHLQFKDQJHIURPEDVHOLQHLQ7(7LVVHFRQGVRUPRUH ZRUVH x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±'DWHRI6WXG\'D\ 2QRUDIWHU6WXG\'D\ 6WXG\'D\ 'DWHRI,QWHUHVW±'DWHRI6WXG\'D\ 7KHUHIRUHWKHGD\SULRUWR6WXG\'D\LV 3RVWEDVHOLQH6WXG\9LVLW 6HH$SSHQGL[$ &RPSOHWLQJ6WXG\ $VXEMHFWLVGHILQHGDVFRPSOHWLQJVWXG\LIWKHSULPDU\UHDVRQIRUHQGLQJVWXG\LV ³&RPSOHWHG´ &RPSOHWLQJ,QYHVWLJDWLRQDO3URGXFW ,3 $VXEMHFWLVGHILQHGDVFRPSOHWLQJ,3LIWKHUHDVRQIRUHQGLQJ,3LV³&RPSOHWHG´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¶V%0,ZLOOEHGHULYHGLQNJPLQWKHFOLQLFDOGDWDEDVH (IILFDF\(QGSRLQWV &KDQJHIURPEDVHOLQHLQ7(7 &KDQJHIURPEDVHOLQHLQ7(7 7(7IURPRQVWXG\(77SRVWUDQGRPL]DWLRQ EDVHOLQH7(7 7LPHWR(YHQW 7LPHWRHYHQW RQVHWRIDQJLQDPP67VHJPHQWGHSUHVVLRQ
Load more

Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Brimonidine Tartrate; Brinzolamide
    Contains Nonbinding Recommendations Draft Guidance on Brimonidine Tartrate ; Brinzolamide This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs. Active Ingredient: Brimonidine tartrate; Brinzolamide Dosage Form; Route: Suspension/drops; ophthalmic Strength: 0.2%; 1% Recommended Studies: One study Type of study: Bioequivalence (BE) study with clinical endpoint Design: Randomized (1:1), double-masked, parallel, two-arm, in vivo Strength: 0.2%; 1% Subjects: Males and females with chronic open angle glaucoma or ocular hypertension in both eyes. Additional comments: Specific recommendations are provided below. ______________________________________________________________________________ Analytes to measure (in appropriate biological fluid): Not applicable Bioequivalence based on (95% CI): Clinical endpoint Additional comments regarding the BE study with clinical endpoint: 1. The Office of Generic Drugs (OGD) recommends conducting a BE study with a clinical endpoint in the treatment of open angle glaucoma and ocular hypertension comparing the test product to the reference listed drug (RLD), each applied as one drop in both eyes three times daily at approximately 8:00 a.m., 4:00 p.m., and 10:00 p.m. for 42 days (6 weeks). 2. Inclusion criteria (the sponsor may add additional criteria): a. Male or nonpregnant females aged at least 18 years with chronic open angle glaucoma or ocular hypertension in both eyes b.
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • The In¯Uence of Medication on Erectile Function
    International Journal of Impotence Research (1997) 9, 17±26 ß 1997 Stockton Press All rights reserved 0955-9930/97 $12.00 The in¯uence of medication on erectile function W Meinhardt1, RF Kropman2, P Vermeij3, AAB Lycklama aÁ Nijeholt4 and J Zwartendijk4 1Department of Urology, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Urology, Leyenburg Hospital, Leyweg 275, 2545 CH The Hague, The Netherlands; 3Pharmacy; and 4Department of Urology, Leiden University Hospital, P.O. Box 9600, 2300 RC Leiden, The Netherlands Keywords: impotence; side-effect; antipsychotic; antihypertensive; physiology; erectile function Introduction stopped their antihypertensive treatment over a ®ve year period, because of side-effects on sexual function.5 In the drug registration procedures sexual Several physiological mechanisms are involved in function is not a major issue. This means that erectile function. A negative in¯uence of prescrip- knowledge of the problem is mainly dependent on tion-drugs on these mechanisms will not always case reports and the lists from side effect registries.6±8 come to the attention of the clinician, whereas a Another way of looking at the problem is drug causing priapism will rarely escape the atten- combining available data on mechanisms of action tion. of drugs with the knowledge of the physiological When erectile function is in¯uenced in a negative mechanisms involved in erectile function. The way compensation may occur. For example, age- advantage of this approach is that remedies may related penile sensory disorders may be compen- evolve from it. sated for by extra stimulation.1 Diminished in¯ux of In this paper we will discuss the subject in the blood will lead to a slower onset of the erection, but following order: may be accepted.
    [Show full text]
  • Interactions Medicamenteuses Index Des Classes Pharmaco
    INTERACTIONS MEDICAMENTEUSES INDEX DES CLASSES PHARMACO-THERAPEUTIQUES Mise à jour avril 2006 acides biliaires (acide chenodesoxycholique, acide ursodesoxycholique) acidifiants urinaires adrénaline (voie bucco-dentaire ou sous-cutanée) (adrenaline alcalinisants urinaires (acetazolamide, sodium (bicarbonate de), trometamol) alcaloïdes de l'ergot de seigle dopaminergiques (bromocriptine, cabergoline, lisuride, pergolide) alcaloïdes de l'ergot de seigle vasoconstricteurs (dihydroergotamine, ergotamine, methylergometrine) alginates (acide alginique, sodium et de trolamine (alginate de)) alphabloquants à visée urologique (alfuzosine, doxazosine, prazosine, tamsulosine, terazosine) amidons et gélatines (gelatine, hydroxyethylamidon, polygeline) aminosides (amikacine, dibekacine, gentamicine, isepamicine, kanamycine, netilmicine, streptomycine, tobramycine) amprénavir (et, par extrapolation, fosamprénavir) (amprenavir, fosamprenavir) analgésiques morphiniques agonistes (alfentanil, codeine, dextromoramide, dextropropoxyphene, dihydrocodeine, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil, tramadol) analgésiques morphiniques de palier II (codeine, dextropropoxyphene, dihydrocodeine, tramadol) analgésiques morphiniques de palier III (alfentanil, dextromoramide, fentanyl, hydromorphone, morphine, oxycodone, pethidine, phenoperidine, remifentanil, sufentanil) analogues de la somatostatine (lanreotide, octreotide) androgènes (danazol, norethandrolone, testosterone) anesthésiques volatils halogénés
    [Show full text]
  • Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg
    OPTOMETRIC STUDY CENTER Table 1. Glaucoma Medications: Mechanisms, Dosing and Precautions Brand Generic Mechanism of Action Dosage/Avg. % Product Sizes Side Effects Warnings Reduction CHOLINERGIC AGENTS Direct Pilocarpine (generic) Pilocarpine 1%, 2%, 4% Increases trabecular outflow BID-QID/15-25% 15ml Headache, blurred vision, myopia, retinal detachment, bronchiole constriction, Angle closure, shortness of breath, retinal narrowing of angle detachment Indirect Phospholine Iodide (Pfizer) Echothiophate iodide 0.125% Increases trabecular outflow QD-BID/15-25% 5ml Same as above plus cataractogenic iris cysts in children, pupillary block, Same as above, plus avoid prior to any increased paralysis with succinylcholine general anesthetic procedure ALPHA-2 AGONISTS Alphagan P (Allergan) Brimonidine tartrate 0.1%, 0.15% with Purite Decreases aqueous production, increases BID-TID/up to 26% 5ml, 10ml, 15ml Dry mouth, hypotension, bradycardia, follicular conjunctivitis, ocular irritation, Monitor for shortness of breath, dizziness, preservative uveoscleral outflow pruritus, dermatitis, conjunctival blanching, eyelid retraction, mydriasis, drug ocular redness and itching, fatigue allergy Brimonidine tartrate Brimonidine tartrate 0.15%, 0.2% Same as above Same as above 5ml, 10ml Same as above Same as above (generic) Iopidine (Novartis) Apraclonidine 0.5% Decreases aqueous production BID-TID/up to 25% 5ml, 10ml Same as above but higher drug allergy (40%) Same as above BETA-BLOCKERS Non-selective Betagan (Allergan) Levobunolol 0.25%, 0.5% Decreases
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]